trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

The ceftazidime-avibactam antibiotic combination is effective against KPC and OXA-48-like serine carbapenemase producing Enterobacteriaceae.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that the ceftazidime-avibactam antibiotic combination is effective against KPC and OXA-48-like serine carbapenemase producing Enterobacteriaceae?

Yes. Clinical evidence and systematic reviews consistently demonstrate that the ceftazidime-avibactam antibiotic combination is effective against both KPC and OXA-48-like serine carbapenemase-producing Enterobacteriaceae.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The claim states that ceftazidime-avibactam is effective against KPC and OXA-48-like serine carbapenemase-producing Enterobacteriaceae. Multiple retrieved papers explicitly support this: Paper 7 (meta-analysis) highlights its superior efficacy for OXA-48-like and KPC producers, Paper 6 notes it is a cornerstone treatment for KPC and a viable option for OXA-48, and Paper 5 demonstrates real-world clinical success against OXA-48 infections. No papers refute the core claim.

Evidence for · 3
P10 Ceftazidime/avibactam for OXA-48 urinary tract infections—a 12 month remissive study
2023
Demonstrates clinical efficiency and safety of ceftazidime/avibactam in treating OXA-48-producing urinary tract infections.
Get citation
Fernandes, A. P., Silva, B., & Coutinho, A. (2023). P10 Ceftazidime/avibactam for OXA-48 urinary tract infections—a 12 month remissive study. doi.org. https://doi.org/10.1093/jacamr/dlad077.014

See more details
More for · 2
Avibactam-based combinations for the treatment of multidrug resistant Gram-negative bacilli infections.
2026
Highlights ceftazidime/avibactam as a cornerstone for treating infections caused by KPC-producing Enterobacterales and a carbapenem-sparing option for OXA-48-producing strains.
Get citation
G, T., A, R., M, B., M, T., & M, F. (2026). Avibactam-based combinations for the treatment of multidrug resistant Gram-negative bacilli infections.. doi.org. https://doi.org/10.53854/liim-3403-2

Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis.
2026
Systematic review and meta-analysis shows that ceftazidime-avibactam is superior for OXA-48-like producers and highly effective against KPC-producing carbapenem-resistant Enterobacterales.
Get citation
BR, A. S. (2026). Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis.. doi.org. https://doi.org/10.3390/antibiotics15090928

also asked as
  • Does ceftazidime-avibactam work against KPC and OXA-48-like serine carbapenemase producing Enterobacteriaceae?
  • Is the antibiotic combination ceftazidime-avibactam effective on KPC and OXA-48-like serine carbapenemase producing Enterobacteriaceae?
  • Can ceftazidime-avibactam treat KPC and OXA-48-like serine carbapenemase producing Enterobacteriaceae infections?
  • Are Enterobacteriaceae that produce KPC and OXA-48-like serine carbapenemase susceptible to ceftazidime-avibactam?
Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work